Journal article
Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
American Society of Clinical Oncology educational book, Vol.43, e390464
06/01/2023
DOI: 10.1200/EDBK_390464
Abstract
Triple-negative breast cancer (TNBC) is a very heterogeneous and aggressive breast cancer subtype with a high risk of mortality, even if diagnosed early. The mainstay of early-stage breast cancer includes systemic chemotherapy and surgery, with or without radiation therapy. More recently, immunotherapy is approved to treat TNBC, but managing immune-rated adverse events while balancing efficacy is a challenge. The purpose of this review is to highlight the current treatment recommendations for early-stage TNBC and the management of immunotherapy toxicities.
Details
- Title: Subtitle
- Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End, and Everything in Between
- Creators
- Hyo Sook Han - Moffitt Cancer CenterPraveen Vikas - University of IowaRicardo L B Costa - Moffitt Cancer CenterNusrat Jahan - University of Alabama at BirminghamAmmanuel Taye - University of Alabama at BirminghamErica M Stringer-Reasor
- Resource Type
- Journal article
- Publication Details
- American Society of Clinical Oncology educational book, Vol.43, e390464
- DOI
- 10.1200/EDBK_390464
- eISSN
- 1548-8756
- Language
- English
- Date published
- 06/01/2023
- Academic Unit
- Internal Medicine; Hematology, Oncology, and Blood & Marrow Transplantation
- Record Identifier
- 9984436458402771
Metrics
3 Record Views